ArriVent reports Q2 2026 results, licenses ARR-002 to Allist in Greater ChinaAug 12Clinical readoutARR-002ArriVent BioPharma, Inc.
ArriVent registers Phase 1 trial of ARR-002 in ovarian and endometrial cancerAug 10Trial updateARR-002ArriVent BioPharma, Inc.
Sign inSign in